Breye Therapeutics is a clinical development stage company that developing new therapies within Opthalmology

The lead program is Danegaptide – an oral drug that can both treat Diabetic Retinopathy and prevent disease progression. Danegaptide can stabilize cell-cell junctions in the retinal capillaries, protect from capillary loss, and prevent vascular leakage and edema.

Sound contact: Johan Kördel (Board Director)

Read an interview with Ulrik Mouritzen, CEO and Founder A visionary journey to innovate sight-preserving therapies

Related news

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

2024.01.252024.05.13 / • Investigating potential for an oral treatment in diabetic retinopathy• First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a …

The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health

2023.11.032024.05.13 / Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Bre …

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

2023.08.082024.05.13 / 25 July 2023 Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neuroscien …

Breye Therapeutics Strengthens Management Team and Board

2023.04.202024.10.07 / Industry veteran Dr. Peter Adamson, PhD appointed as Chief Scientific Officer Dr. Gabriela Burian, MD appointed to the Board of Directors Copenhagen, Denmark, 20 April 2023 – Breye Therapeuti …

A visionary journey to innovate sight-preserving therapies

2023.01.252024.05.13 / Breye Therapeutics is all about the people. Whether it’s the company’s team or the patients whose eyesight they seek to protect, the focus is consistently on the human factor. It’s a value influenced …

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

2022.11.102024.05.13 / Industry expert Ulrik Mouritzen M.D. appointed Chief Executive OfficerFunding to advance lead asset to phase 1b clinical trial and further build pipeline Copenhagen, Denmark, 10 November 2022 – Br …

Sound Contact:

Johan Kördel

Ph.D., Managing Partner